QB3 Collaborative Startups is a partnership between industry, QB3, and entrepreneurs that ensures startups are optimally structured, operationally efficient, and funded to succeed.
The global drug giant announced Wednesday that it signed a three-year deal with QB3 and its seed stage venture fund to jointly evaluate, fund and work with startup companies.
At least three pharmaceutical companies have signed on to a program that essentially puts QB3 in the role of business development. Reported in the San Francisco Business Times (paywall).
Submitted by kaspar mossman on April 17, 2013 - 3:52pm
The awards help UC researchers take their life science technologies across the “valley of death.” Of the 11 projects funded between 2007-2011, nine have already been commercialized. This is an extraordinary success rate.
San Francisco Business Times reporter Ron Leuty interviews QB3 Entrepreneurship Program Manager Adriana Tajonar about our membership program for startups.
Submitted by kaspar mossman on October 29, 2012 - 11:37am
Universities not only provide the ideal petri dish for cultivating bioscience with commercial potential, but have a moral obligation to do so, given the opportunity to translate public funding into health and jobs, according to a study published by QB3.
The j5 software package for sequencing, splicing and expressing DNA is the basis for TeselaGen, a tenant of the QB3/PharmChem Digital Garage at UCSF Mission Bay.
Submitted by kaspar mossman on September 19, 2012 - 11:19am
QB3 Startup in a Box, which initially aimed at helping 15 wannabe life sciences entrepreneurs blow past barriers to launching companies, has aided 76 startups since it began a year ago — and it is pushing deeper into the Bay Area.
Ronald Vale, of QB3-UCSF, was one of three scientists awarded the 2012 Albert Lasker Basic Medical Research Award. His work has helped illuminate how the heart beats and how cells transport material internally.
